Delisting risk
Lisata Therapeutics (LSTA)
Develops certepetide for tumor-penetrating cancer therapy combinations.
$1.57
At close0.00 (0.00%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions34 holders · as of Mar 31, 2026 | 11.74% | 1.06M shares | |
| Insiders10 holders · as of Aug 26, 2026 | 15.69% | 1.41M shares | |
| Otherremainder | 72.57% | 6.54M shares |
9.01M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
34 holders · 1.06M shares · 14 new positions · 19 increased · 3 reduced · 5 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 271.8K | 3.02% | +271.8Knew | May 15, 2026 |
| Renaissance Technologies LLC | 131.7K | 1.46% | +8.0K | May 14, 2026 |
| Deltec Asset Management LLC | 90.0K | 1.00% | +90.0Knew | Apr 24, 2026 |
| Rangeley Capital, LLC | 75.0K | 0.83% | +75.0Knew | May 15, 2026 |
| Geode Capital Management, LLC | 70.9K | 0.79% | +6.5K | May 15, 2026 |
| CSS LLC/IL | 61.9K | 0.69% | +61.9Knew | May 15, 2026 |
| BlackRock, Inc. | 54.9K | 0.61% | 0 | May 13, 2026 |
| Penderfund Capital Management Ltd. | 47.5K | 0.53% | +47.5Knew | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Branham Justin Earl | 5.10% | 462.1K | 13G | Aug 26, 2026 ↗ |
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.